The Management of Peyronie's Disease: Evidence-based 2010 Guidelines

Journal of Sexual Medicine

Volumn 7, Issue 7, 2010, Pages 2359-2374

  Ralph, David ^a   Gonzalez Cadavid, Nestor ^b   Mirone, Vincenzo ^c   Perovic, Sava ^d   Sohn, Michael ^e   Usta, Mustafa ^f   Levine, Laurence ^g  

^a Institute of Urology   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f AKDENIZ UNIVERSITY   (Turkey)

^g RUSH MEDICAL COLLEGE   (United States)

Author keywords

Guidelines; Pathology; Peyronie's Disease; Surgery

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; COLCHICINE; COLLAGENASE; DEXAMETHASONE; PENTOXIFYLLINE; PLACEBO; PROPIONYLCARNITINE; STEROID; TAMOXIFEN; VERAPAMIL;

ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMORBIDITY; CONSENSUS DEVELOPMENT; CONSERVATIVE TREATMENT; DRUG EFFICACY; ECHOGRAPHY; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; EXTRACORPOREAL LITHOTRIPSY; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; IONTOPHORESIS; PATHOGENESIS; PATIENT ASSESSMENT; PENIS PROSTHESIS; PEYRONIE DISEASE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REHABILITATION CARE; SURGICAL APPROACH; SURGICAL TECHNIQUE; TISSUE GRAFT; TRACTION THERAPY; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 77955161053     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01850.x     Document Type: Article

References (190)

1. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004, 1:6-23.
2. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int 2001, 88:727-30.
3. Deveci S, Hopps C, O'Brien K, Parker M, Guhring P, Mulhall JP. Defining the clinical characteristics of peyronie's disease in young men. J Sex Med 2007, 4:485-90.
4. Kendirci M, Trost L, Sikka SC, Hellstrom GJ. Diabetes mellitus is associated with severe Peyronie's disease. BJU Int 2007, 99:383-6.
5. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002, 68:1075-9.
6. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006, 175:2115-8.
7. Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie's disease. Int J Impot Res 2003, 15(5):S103-12. suppl
8. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Peyronie's disease. J Sex Med 2004, 1:110-5.
9. Pryor JP, Ralph DJ. Clinical presentations of Peyronie's disease. Int J Impot Res 2002, 14:414-7.
10. Bella AJ, Sener A, Foell K, Brock GB. Nonpalpable scarring of the penile septum as a cause of erectile dysfunction: An atypical form of Peyronie's disease. J Sex Med 2007, 4:226-30.
11. Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, Gonzalez-Cadavid NF. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: Implications for peyronie disease. Biol Reprod 2005, 73:1199-210.
12. Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie's disease patients: Comparison of three methods. J Sex Med 2007, 4:199-203.
13. Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, Levine L. Impact of Peyronie's disease on sexual and psychosocial functioning: Qualitative findings in patients and controls. J Sex Med 2008, 5:1977-84.
14. Smith JF, Conti S, Walsh TJ, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie's disease. J Sex Med 2008, 5:2179-84.
15. Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie's disease. J Sex Med 2008, 5:1985-90.
16. Amin Z, Patel U, Friedman EP, Vale JA, Kirby R, Lees WR. Colour Doppler and duplex ultrasound assessment of Peyronie's disease in impotent men. B J Rad 1993, 66:398-402.
17. Kadioglu A, Oktar T, Kandirali E, Kendirci M, Sanli O, Ozsoy C. Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction. Int J Impot Res 2004, 16:540-3.
18. Gasior BL, Levine FJ, Howannesian A, Krane RJ, Goldstein I. Plaque-associated corporal venoocclusive dysfunction in idiopathic Peyronie's disease: A pharmacocavernosometric and pharmacocavernosographic study. World J Urol 1990, 8:90-6.
19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile function (IIEF): A multidimensional scale for the assessment of erectile dysfunction. Urology 1997, 49:822-30.
20. Hauck EW, Hackstein N, Vosshenrich R, Diemer T, Schmelz HU, Bschleipfer T, Schroeder-Printzen I, Weidner W. Diagnostic value of magnetic resonance imaging in Peyronie's disease-A comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol 2003, 43:293-300.
21. Aversa A, Sarteschi LM. The role of penile colorduplex ultrasound for the evaluation of erectile dysfunction. J Sex Med 2007, 4:1437-47.
22. Kadioglu A, Tefekli A, Erol H, Cayan S, Kandirali E. Color Doppler ultrasound assessment of penile vascular system in men with Peyronie's disease. Int J Impot Res 2000, 12:263-7.
23. LaRochelle JC, Levine LA. A survey of primary care physicians and urologists regarding Peyronie's disease. J Sex Med 2007, 4:1167-73.
24. Müller A, Mulhall JP. Peyronie's disease intervention trials: Methodological challenges and issues. J Sex Med 2009, 6:848-61.
25. Smith JF, Walsh TJ, Lue TF. Peyronie's disease: A critical appraisal of current diagnosis and treatment. Int J Impot Res 2008, 20:445-59.
26. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med 2007, 4:1527-38.
27. Taylor FL, Levine LA. Peyronie's disease. Urol Clin North Am 2007, 34:vi-34.
28. Greenfield JM, Levine LA. Peyronie's disease: Etiology, epidemiology and medical treatment. Urol Clin North Am 2005, 32:469-78.
29. Smith CJ, McMahon C, Shabsigh R. Peyronie's disease: The epidemiology, aetiology and clinical evaluation of deformity. BJU Int 2005, 95:729-32.
30. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodósio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie's disease in men over 50-year-old from Southern Brazil. Int J Impot Res 2001, 13:291-3.
31. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004, 171:2350-3.
32. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F. SIMONA Study Group. Peyronie's disease: Prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol 2000, 40:525-30.
33. Kumar B, Narang T, Gupta S, Gulati M. A clinico-aetiological and ultrasonographic study of Peyronie's disease. Sex Health 2006, 3:113-18.
34. El-Sakka AI. Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur Urol 2006, 49:564-69.
35. Tefekli A, Kandirali E, Erol B, Tunc M, Kadioglu A. Peyronie's disease: A silent consequence of diabetes mellitus. Asian J Androl 2006, 8:75-9.
36. Usta MF, Bivalacqua TJ, Tokatli Z, Rivera F, Gulkesen KH, Sikka SC, Hellstrom WJ. Stratification of penile vascular pathologies in patients with Peyronie's disease and in men with erectile dysfunction according to age: A comparative study. J Urol 2004, 172:259-62.
37. Usta MF, Bivalacqua TJ, Jabren GW, Myers L, Sanabria J, Sikka SC, Hellstrom WJ. Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease. J Urol 2004, 171:775-9.
38. El-Sakka AI, Tayeb KA. Peyronie's disease in diabetic patients being screened for erectile dysfunction. J Urol 2005, 174:1026-30.
39. Tefekli A, Kandirali E, Erol H, Alp T, Köksal T, Kadioglu A. Peyronie's disease in men under age 40: Characteristics and outcome. Int J Impot Res 2001, 13:18-23.
40. Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol 1998, 51:511-5.
41. Perimenis P, Athanasopoulos A, Gyftopoulos K, Katsenis G, Barbalias G. Peyronie's disease: Epidemiology and clinical presentation of 134 cases. Int Urol Nephrol 2001, 32:691-4.
42. Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's disease: A casecontrol study. BJU Int 2006, 97:570-4.
43. Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res 2007, 19:213-7.
44. Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie's disease: Implications for new therapies. J Sex Med 2009, 6:303-13.
45. Gonzalez-Cadavid NF, Rajfer J. Experimental models for the study of the cellular and molecular pathophysiology of Peyronie's disease. Current clinical urology: Peyronie's disease, a guide to clinical management 2007, 19-39. Levine LA, ed., Totowa, NJ, Humana Press
46. Sasso F, Gulino G, Falabella R, D'Addessi A, Sacco E, D'Onofrio A, Bassi PF. Peyronie's disease: Lights and shadows. Urol Int 2007, 78:1-9.
47. Devine CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 1997, 157:285-90.
48. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997, 157:311-5.
49. Van de Water L. Mechanisms by which fibrin and fibronectin appear in healing wounds: Implications for Peyronie's disease. J Urol 1997, 157:306-10.
50. Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 2005, 65:645-8.
51. Ehrlich HP. Scar contracture: Cellular and connective tissue aspects in Peyronie's disease. J Urol 1997, 157:316-9.
52. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: A new animal model of Peyronie's disease. BJU Int 2003, 91:830-8.
53. Davila HH, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol Reprod 2004, 71:1568-77.
54. Zargooshi J. Trauma as the cause of Peyronie's disease: Penile fracture as a model of trauma. J Urol 2004, 172:186-8.
55. El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF. The effect of surgical trauma on rat tunica albuginea. J Urol 1998, 159:1700-7.
56. Schiavino D, Sasso F, Nucera E, Alcini E, Gulino G, Milani A, Patriarca G. Immunologic findings in Peyronie's disease: A controlled study. Urology 1997, 50:764-8.
57. Noss MB, Day NS, Christ GJ, Melman A. The genetics and immunology of Peyronie's disease. Int J Impot Res 2000, 12(4):S127-32. suppl
58. Hauck EW, Hauptmann A, Weidner W, Bein G, Hackstein H. Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie's disease. J Urol 2003, 170:1443-6.
59. Hauck EW, Hauptmann A, Haag SM, Bohnert A, Weidner W, Bein G, Hackstein H. Alpha-1-antitrypsin levels and genetic variation of the alpha-1-antitrypsin gene in Peyronie's disease. Eur Urol 2004, 46:623-8. discussion 628
60. Hauck EW, Hauptmann A, Schmelz HU, Bein G, Weidner W, Hackstein H. Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease. J Urol 2003, 169:369-72.
61. Ralph DJ, Schwartz G, Moore W, Pryor JP, Ebringer A, Bottazzo GF. The genetic and bacteriological aspects of Peyronie's disease. J Urol 1997, 157:291-4.
62. Domes T, De Young L, O'Gorman DB, Gan BS, Bella AJ, Brock G. Is there a role for proteomics in Peyronie's disease? J Sex Med 2007, 4:867-77.
63. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002, 6:283-94.
64. Iacono F, Barra S, de Rosa G, Boscaino A, Lotti T. Microstructural disorders of tunica albuginea in patients affected by impotence. Eur Urol 1994, 26:233-39.
65. Anafarta K, Bedük Y, Uluoglu O, Aydos K, Baltaci S. The significance of histopathological changes of the normal tunica albuginea in Peyronie's disease. Int Urol Nephrol 1994, 26:71-7.
66. Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997, 157:276-81.
67. Mirone V, Imbimbo C, Palmieri A, Longo N, Fusco F, Tajana G. A new biopsy technique to investigate Peyronie's disease associated histologic alterations: Results with two different forms of therapy. Eur Urol 2002, 42:239-44. discussion 244
68. Somers KD, Sismour EN, Wright GL, Devine CJ, Gilbert DA, Horton CE. Isolation and characterization of collagen in Peyronie's disease. J Urol 1989, 141:629-31.
69. Gentile V, Modesti A, La Pera G, Vasaturo F, Modica A, Prigiotti G, Di Silverio F, Scarpa S. Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive dysfunction. J Androl 1996, 17:96-103.
70. Davis CJ. The microscopic pathology of Peyronie's disease. J Urol 1997, 157:282-4.
71. Hirano D, Takimoto Y, Yamamoto T, Hirakata H, Kawata N. Electron microscopic study of the penile plaques and adjacent corpora cavernosa in Peyronie's disease. Int J Urol 1997, 4:274-78.
72. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002, 7:262-76.
73. Eyden B. The myofibroblast: Phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med 2008, 12:22-37.
74. Vernet D, Magee T, Qian A, Nolazco G, Rajfer J, Gonzalez-Cadavid N. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med 2006, 3:84-94. discussion 94-5
75. Vande Berg JS, Devine CJ, Horton CE, Somers KD, Wright GL, Leffell MS, Dawson DM, Gleischman SH, Rowe MJ. Mechanisms of calcification in Peyronie's disease. J Urol 1982, 127:52-4.
76. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158:2284-90.
77. El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br J Urol 1998, 81:445-52.
78. El-Sakka AI, Bakircioglu ME, Bhatnagar RS, Yen TS, Dahiya R, Lue TF. The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol 1999, 161:1980-3.
79. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, Kadowitz PJ, Hellstrom WJ. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000, 163:1992-8.
80. Bivalacqua TJ, Champion HC, Leungwattanakij S, Yang DY, Hyun JS, Abdel-Mageed AB, Sikka SC, Kadowitz PJ, Hellstrom WJ. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's-like condition in the rat. J Androl 2001, 22:497-506.
81. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003, 9:229-44.
82. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006, 97:625-33.
83. Cantini LP, Ferrini MG, Vernet D, Magee TR, Qian A, Gelfand RA, Rajfer J, Gonzalez-Cadavid NF. Profibrotic role of myostatin in Peyronie's disease. J Sex Med 2008, 5:1607-22.
84. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
85. Piao S, Ryu JK, Shin HY, Zhang L, Song SU, Han JY, Park SH, Kim JM, Kim IH, Kim SJ, Suh JK. Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: A useful model for the study of Peyronie's disease. Int J Androl 2008, 31:346-53.
86. Lucattelli M, Lunghi B, Fineschi S. A new mouse model of Peyronie's disease: An increased expression of hypoxia-induciblefactor-1 target genes during the development of penile changes. Int J Biochem Cell Biol 2008, 40:2638-48.
87. Somers KD, Dawson DM, Wright GL, Leffell MS, Rowe MJ, Bluemink GG, Vande Berg JS, Gleischman SH, Devine CJ, Horton CE. Cell culture of Peyronie's disease plaque and normal penile tissue. J Urol 1982, 127:585-8.
88. Mulhall JP, Nicholson B, Pierpaoli S, Lubrano T, Shankey TV. Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie's disease. Int J Impot Res 2004, 16:288-93.
89. Mulhall JP, Branch J, Lubrano T, Shankey TV. Perturbation of cell cycle regulators in Peyronie's disease. Int J Impot Res 2001, 13(5):S21-8. suppl
90. Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie's disease. J Urol 2001, 165:419-23.
91. Mulhall JP, Branch J, Lubrano T, Shankey TV. Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts. J Urol 2003, 170:281-4.
92. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 2002, 14:397-405.
93. Mulhall JP, Martin DJ, Lubrano T, Moser M, Kwon E, Wojcik E, Shankey TV. Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res 2004, 16:99-104.
94. Mulhall JP. Expanding the paradigm for plaque development in Peyronie's disease. Int J Impot Res 2003, 15(5):S93-102. suppl
95. Haag SM, Hauck EW, Eickelberg O, Szardening- Kirchner C, Diemer T, Weidner W. Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie's disease. Eur Urol 2008, 53:425-30. Epub 2007 Jun 27
96. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: One function, multiple origins. Am J Pathol 2007, 170:1807-16.
97. Nolazco G, Kovanecz I, Vernet D, Gelfand RA, Tsao J, Ferrini MG, Magee T, Rajfer J, Gonzalez-Cadavid NF. Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int 2008, 101:1156-64.
98. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med 2009, 6(3):353-62. suppl
99. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391-4.
100. Lin CS, Lin G, Wang Z, Maddah SA, Lue TF. Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease. Biochem Biophys Res Commun 2002, 295:1014-9.
101. Wang Z, Lin G, Lue TF, Lin CS. Wogonin suppresses cellular proliferation and expression of monocyte chemoattractant protein 1 in Peyronie's plaque-derived cells. BJU Int 2003, 92:753-7.
102. Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase on the physiology and pathology of penile erection. Curr Pharm Des 2005, 11:4041-46.
103. Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008, 179:2447-55.
104. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J Urol 1993, 149:56-8.
105. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: New insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol 2005, 2:291-7.
106. Magee TR, Qian A, Rajfer J, Sander FC, Levine LA, Gonzalez-Cadavid NF. Gene expression profiles in the Peyronie's disease plaque. Urology 2002, 59:451-7.
107. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004, 64:399-404.
108. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, Gonzalez-Cadavid NF. Longterm continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis. Biol Reprod 2007, 76:915-23.
109. Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, Gonzalez-Cadavid N. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction (CVOD) that occurs following cavernosal nerve resection in the rat. BJU Int 2008, 101:203-10.
110. Zarafonetis CJD, Horrax TM. Treatment of Peyronie's disease with potassium paraaminobenzoate (Potaba). J Urol 1959, 81:770-2.
111. Shah PJR, Green NA, Adib RS, Pryor JP. A multicentre doubleblind controlled clinical trial of potassium-para-aminobenzoate (Potaba) in Peyronie's disease. Prog Reprod Biol Med 1983, 9:61-7.
112. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: A prospective, placebocontrolled, randomized study. Eur Urol 2005, 47:530-6.
113. Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie's disease: A nationwide survey. J Sex Med 2008, 5:954-64. Epub 2007 Nov 27
114. Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol Med 1983, 9:41-5.
115. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-Lcarnitine, separately or in combination, in patients with early chronic Peyronie's disease: A doubleblind, placebo controlled, randomized study. J Urol 2007, 178:1398-403.
116. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992, 70:648-51.
117. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999, 162:2003-5.
118. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994, 44:291-5.
119. Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: Long-term results and predictive parameters of successful outcome. Int J Impot Res 2000, 12:169-75.
120. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: A randomized double-blind, placebo-controlled study. Int J Impot Res 2004, 16:238-43.
121. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003, 91:522-4.
122. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. BJU Int 2001, 88:63-7.
123. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002, 89:895-900.
124. Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol 2006, 3:37-5.
125. Winter CC, Khanna R. Peyronie's disease: Results with dermo-jet injection of dexamethasone. J Urol 1975, 114:898-900.
126. Desanctis PN, Furey CA. Steroid injection therapy for Peyronie's disease: A 10-year summary and review of 38 cases. J Urol 1967, 97:114-6.
127. Teasley GH. Peyronie's disease: A new approach. J Urol 1954, 71:611-4.
128. Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol 1980, 52:392-5.
129. Toksu E. Peyronie's disease: A method of treatment. J Urol 1971, 105:523-4.
130. Furey CA. Peyronie's disease: Treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957, 77:251-66.
131. Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R. Betamethasone versus placebo in Peyronie's disease. Arch Ital Urol Androl 1998, 70:165-8.
132. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: A prospective, single-center, non-placebocontrolled study. J Sex Med 2008, 5:180-7.
133. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994, 151:1522-24.
134. Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997, 158:1395-99.
135. Levine LA, Goldman K, Greenfield J. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002, 168:621-26.
136. Anderson MS, Shankey TV, Lubrano T, Mulhall JP. Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000, 12(3):S25-31. suppl
137. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single-blind study. Urology 1998, 51:620-6.
138. Bennet NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease. J Urol 2007, 69:1181-4.
139. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007, 69:950-4.
140. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough A, Hakim LS, Nehra A. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006, 176:394-8.
141. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: A randomized and prospective study. Urology 2006, 67:1038-42.
142. Michel MS, Ptaschnyk T, Musial A, Braun P, Lenz ST, Alken P, Köhrmann KU. Objective and subjective changes in patients with Peyronie's disease after management with shock wave therapy. J Endourol 2003, 17:41-4.
143. Strebel RT, Suter S, Sautter T, Hauri D. Extracorporeal shock wave therapy for Peyronie's disease does not correct penile deformity. Int J Impot Res 2004, 16:448-51.
144. Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy in Peyronie's disease: Results of a prospective approach. J Urol 2004, 171:269-99.
145. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease: Exploratory meta-analysis of clinical trials. J Urol 2004, 171:740-5.
146. Srirangam SJ, Manikandan R, Hussain J, Collins GN, O'Reilly PH. Long-term results of extracorporeal shockwave therapy for Peyronie's disease. J Endourol 2006, 20:880-4.
147. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. A first prospective, randomized, double-blind, placebo- controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009, 56:363-70.
148. Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H. Iontophoresis for treatment of Peyronie's disease. J Urol 2000, 163:95-9.
149. Di Stasi S, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004, 171:1605-8.
150. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: A double-blind, placebo controlled trial. J Urol 2007, 177:972-5.
151. Li J, Duncan RL, Burr DB, Turner CH. L-type calcium channels mediate mechanically induced bone formation in vivo. J Bone Miner Res 2003, 18:58-66.
152. Alman BA, Greel DA, Ruby LK, Goldberg MJ, Wolfe HJ. Regulation of proliferation and platelet-derived growth factor expression in palmar fibromatosis (Dupuytren contracture) by mechanical strain. J Orthop Res 1996, 14:38-8.
153. Brighton CT, Fisher JRS, Levine SE, Corsetti JR, Reilly T, Landsman AS, Williams JL, Thibault LE. The biochemical pathway mediating the proliferative response of bone cells to a mechanical stimulus. J Bone Joint Surg Am 1996, 78:1337-47.
154. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: A single-center pilot study. J Sex Med 2008, 5:1468-73.
155. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, Mondaini N. Use of penile extender device in the treatment of penile curvature as a result of peyronie's disease. Results of a phase ii prospective study. J Sex Med 2009, 6:559-66.
156. Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie's disease. Curr Opin Urol 2004, 6:381-8.
157. Taylor FL, Levine LA. Surgical correction of Peyronie's disease using Tunica albuginea plication or partial plaque excision with pericardial graft: Long-term followup. J Sex Med 2008, 5:2221-8.
158. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunical albuginea plication for correction of penile curvature. J Urol 2006, 175:238-41.
159. Levine LA, Greenfield JM, Estrada CR. Erectile dysfunction following surgical correction of Peyronie's disease and a pilot study of the use of Sildenafil citrate rehabilitation for postoperative erectile dysfunction. J Sex Med 2007, 5:241-7.
160. Dimitriou R, Levine LA. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie's Disease. J Urol 1999, 161:1014A.
161. Levine LA, Lenting E. A surgical algorithm for the treatment of Peyronie's disease. J Urol 1997, 158:2149-52.
162. Mulhall JP, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: Functional and satisfaction outcomes. J Sex Med 2005, 2:132-8.
163. Ralph DJ, Minhas S. The management of Peyronie's disease. BJU Int 2004, 93:208-15.
164. Ralph DJ, al-Akraa M, Pryor JP. The Nesbit operation for Peyronie's disease: 16-year experience. J Urol 1995, 4:1362-3.
165. Essed E, Schroeder F. New surgical technique for Peyronie's disease. Urology 1985, 25:582-7.
166. Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol 1990, 143:80-2.
167. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: A review of 132 patients. J Urol 2002, 167:2066-9.
168. Bella AJ, Brock GB. Minimally invasive intracorpal incision of peyronie's plaque. Peyronie's Disease. A guide to clinical management 2007, 241-7. Levine LA, ed., Totowa, NJ, Humana Press
169. Daitch J, Angermeier K, Montague D. Modified corporoplasty for penile curvature: Long-term results and patient satisfaction. J Urol 1999, 162:2006-9.
170. Rolle L, Tamagnone A, Timpano M, Destefanis P, Fiori C, Ceruti C, Fontana D. The Nesbit operation for penile curvature: An easy and effective technical modification. J Urol 2005, 173:171-3.
171. Savoca G, Scieri F, Petropaolo F, Garaffa G, Belgrano E. Straightening corporoplasty for Peyronie's disease: A review of 218 patients with median follow-up of 89 months. Eur Urol 2004, 46:610-4.
172. Syed AH, Abbasi Z, Hargreave TB. Nesbit procedure for disabling Peyronie's curvature: A median follow-up of 84 months. Urology 2003, 61:999-1003.
173. Dalkin BL, Carter MF. Venogenic impotence following dermal graft repair for Peyronie's disease. J Urol 1991, 146:849-51.
174. Gelbard MK. Relaxing incisions in the correction of penile deformity due to Peyronie's disease. J Urol 1995, 154:1457-60.
175. Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie's disease. J Sex Med 2007, 4:1500-8.
176. Leungwattanakij S, Bivalacque TJ, Reddy S, Hellstrom WJ. Long-term follow-up on use of pericardial graft in the surgical management of Peyronie's disease. Int J Impot Res 2001, 13:183-6.
177. Choi JM, Alex B, Mulhall J. Erectile dysfunction after plaque incision and grafting: Incidence and predictors. 2008, Abstract 730. Annual Meeting of the American Urological Association
178. Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie's disease surgery: A comprehensive review. J Sex Med 2007, 4:581-95.
179. Brannigan RE, Kim ED, Oyasu R, McVary KT. Comparison of tunica albuginea substitute for the treatment of Peyronie's disease. J Urol 1998, 159:1064-8.
180. Edygio PH, Lucon AM, Arap S. Treatment of Peyronie's disease by incomplete circumferential incession of the tunica albuginea and plaque with bovine pericardium graft. Urology 2002, 59:570-4.
181. Moncata-Iribarren I, Jara J, Martinez-Salamanca JI, Cabello R, Hernandez C. Managing penile shortening after Peyronie's disease surgery: A comprehensive review. J Sex Med 2007, 177(4):750. suppl, abstract
182. Knoll LD. Use of small intestinal submucosa graft for the surgical management of Peyronie's disease. J Urol 2007, 178:2474-8.
183. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Ioannidis E. Corporoplasty using tunica albuginea free grafts of penile curvature: Surgical technique and longterm results. J Urol 2002, 167:1367-70.
184. Lue TF, El-Sakka AI. Venous patch graft for Peyronie's disease. Part I: Technique. J Urol 1998, 160:2047-9.
185. Levine LA, Estrada CR. Human cadaveric pericardial graft for the surgical correction of Peyronie's disease. J Urol 2003, 170:2359-62.
186. Breyer BN, Brant WO, Garcia MM, Bella AJ, Lue TF. Complications of porcine small intestine submucosa graft for Peyronie's disease. J Urol 2007, 177:589-91.
187. Hsu GL, Chen HS, Hsieh CH, Chen RM, Wen HS, Liu LJ, Chua C. Long-term results of autologous venous grafts for penile morphological reconstruction. J Androl 2007, 28:186-93.
188. Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie's disease. BJU Int 2005, 95:1029-33.
189. Montorsi F, Salonia A, Briganti A, Dehò F, Zanni G, Luigi DP, Rigatti P. Five year follow up of plaque incision and vein grafting for Peyronie's disease. 2004, Abstract 1256. Annual Meeting of the American Urological Association
190. Wilson SK. Delk 2nd JR. A new treatment for Peyronie's disease: Modeling the penis over an inflatable penile prothesis. J Urol 1994, 152:1121-3.